Metsera Inc. released early clinical data indicating their long-acting amylin analogue, MET-233i, induces significant dose-dependent weight loss with an extended half-life supporting once-monthly dosing. The drug demonstrated up to 8.4% placebo-adjusted weight reduction in Phase I trials, positioning it as a novel challenger to existing weekly GLP-1 receptor agonists in obesity management. Metsera plans to explore combination therapies leveraging MET-233i’s complementary profile.